Cardiol Therapeutics (TSE:CRDL) Hits New 12-Month High – Still a Buy?

Cardiol Therapeutics Inc. (TSE:CRDL) hit a new 52-week high during trading on Wednesday . The stock traded as high as C$3.23 and last traded at C$3.19, with a volume of 299583 shares trading hands. The stock had previously closed at C$3.06.

Cardiol Therapeutics Price Performance

The stock has a market cap of C$364.49 million, a price-to-earnings ratio of -9.18 and a beta of 0.58. The stock’s 50 day moving average price is C$2.11 and its two-hundred day moving average price is C$1.82. The company has a quick ratio of 6.84, a current ratio of 5.55 and a debt-to-equity ratio of 0.45.

Cardiol Therapeutics (TSE:CRDL) last posted its earnings results on Wednesday, August 12th. The company reported C($0.05) earnings per share (EPS) for the quarter. Equities research analysts forecast that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.